Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
6.91
Aug 11 • 12:45 PM ET Dollar change+0.24 Percentage change(3.57%)
Today, 10:15 AMAchieve Life Sciences targets Q4 2026 NDA resubmission for cytisinicline, anticipates FDA approval in first half 2027
Index
RUT
Market Cap
709.16M
Enterprise Value
694.84M
Income
-51.99M
Sales
0.00M
Book/sh
0.20
Cash/sh
0.29
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
28
IPO
Oct 12, 1995
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
34.44
P/C
24.23
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
2.62
Current Ratio
2.62
Debt/Eq
1.40
LT Debt/Eq
0.87
Option/Short
Yes / Yes
EPS (ttm)
-1.12
EPS next Y
-0.58
EPS next Q
-0.18
EPS this Y
40.72%
EPS next Y
21.11%
EPS next 5Y
-
EPS past 3/5Y
32.06% 25.38%
Sales past 3/5Y
- -
EPS Y/Y TTM
16.68%
Sales Y/Y TTM
-
EPS Q/Q
48.49%
Sales Q/Q
-
Insider Own
25.15%
Insider Trans
0.00%
Inst Own
31.04%
Inst Trans
16.38%
ROA
-171.97%
ROE
-496.15%
ROIC
-259.94%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
8.48%
SMA50
15.50%
SMA200
42.12%
Trades
Shs Outstand
102.66M
Shs Float
76.84M
52W High
7.11 -2.84%
52W Low
2.37 191.37%
Volatility
4.15% 5.71%
ATR (14)
0.35
RSI (14)
66.50
Beta
2.22
Rel Volume
0.97
Avg Volume
1.79M
Volume
907,389
Perf Week
6.77%
Perf Month
13.24%
Perf Quarter
23.58%
Perf Half Y
59.54%
Perf YTD
38.99%
Perf Year
181.96%
Perf 3Y
30.09%
Perf 5Y
-11.21%
Perf 10Y
-99.64%
Prev Close
6.67
Price
6.91
Change %
3.57%
Date Action Analyst Rating Change Price Target Change
Jun-26-26Resumed Raymond James Strong Buy $20
Apr-21-26Initiated Canaccord Genuity Buy $13
Nov-25-25Initiated Citizens JMP Mkt Outperform $19
Aug-21-25Initiated H.C. Wainwright Buy $12
Nov-14-24Initiated Rodman & Renshaw Buy $12
Sep-27-24Initiated Raymond James Strong Buy $20
May-10-23Reiterated Maxim Group Buy $8 → $20
Jun-23-21Initiated Oppenheimer Outperform $23
Today 08:30AM
Aug-03-26 08:30AM
Jul-31-26 08:30AM
Jun-29-26 08:30AM
Jun-22-26 08:30AM
08:30AM Loading…
Jun-02-26 08:30AM
May-19-26 02:15PM
May-12-26 07:04PM
12:55PM
07:05AM
07:00AM
May-05-26 08:30AM
Apr-16-26 08:57AM
08:53AM
Apr-15-26 08:00AM
08:30AM Loading…
Mar-26-26 08:30AM
Mar-25-26 08:30AM
Mar-24-26 03:02PM
02:23PM
07:00AM
Mar-17-26 08:30AM
Mar-04-26 08:00AM
Feb-02-26 07:32PM
Jan-30-26 04:05PM
Jan-12-26 08:47AM
Dec-17-25 04:11PM
Dec-08-25 04:10PM
Nov-25-25 08:40AM
Nov-06-25 04:01PM
07:00AM
08:30AM Loading…
Nov-03-25 08:30AM
Oct-29-25 08:30AM
Oct-22-25 03:31PM
Oct-20-25 08:30AM
08:25AM
Oct-17-25 04:21PM
07:30AM
Oct-02-25 04:01PM
Sep-22-25 08:30AM
Sep-18-25 08:30AM
Sep-11-25 05:01PM
Sep-03-25 08:30AM
Sep-02-25 08:30AM
Aug-25-25 10:30AM
Aug-21-25 02:11PM
Aug-07-25 07:30AM
Jul-29-25 08:30AM
Jul-24-25 08:30AM
Jul-13-25 06:15AM
Jul-07-25 08:56AM
Jul-06-25 04:00AM
Jun-30-25 07:52PM
Jun-26-25 11:43PM
04:03PM
04:02PM
04:01PM
May-28-25 08:30AM
May-20-25 08:30AM
May-14-25 03:06AM
01:56AM
May-13-25 07:30AM
May-06-25 08:30AM
Apr-22-25 11:26AM
Apr-21-25 11:19AM
Mar-20-25 06:25PM
Mar-12-25 03:14AM
03:02AM
Mar-11-25 07:30AM
Mar-07-25 08:30AM
Mar-06-25 08:30AM
Feb-18-25 07:29AM
Feb-11-25 08:30AM
Feb-10-25 08:30AM
Jan-24-25 12:14PM
Jan-10-25 08:30AM
Jan-07-25 08:30AM
Jan-06-25 08:30AM
Jan-02-25 11:04AM
Dec-09-24 08:30AM
Dec-03-24 08:30AM
Nov-14-24 08:30AM
Nov-08-24 02:01PM
Nov-07-24 04:05PM
Oct-24-24 08:00AM
Oct-23-24 08:00AM
Oct-16-24 08:00AM
Oct-10-24 08:00AM
Oct-01-24 08:45AM
Aug-26-24 04:30PM
Aug-13-24 04:01PM
Jul-31-24 08:00AM
Jul-29-24 08:00AM
Jul-25-24 08:00AM
Jul-15-24 08:00AM
Jul-09-24 08:00AM
Jul-01-24 08:00AM
May-29-24 08:00AM
May-17-24 08:00AM
May-13-24 08:55AM
May-10-24 03:47PM
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Bothell, WA.
Chief Legal OfficerMr. Erik Atkisson
CEODr. Andrew D. Goldberg M.D.
Chief Financial OfficerMr. Mark K. Oki CPA
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Oki Mark KChief Financial OfficerSep 18 '25Option Exercise0.00168,0000178,000Sep 22 04:31 PM
Oki Mark KChief Financial OfficerSep 18 '25Sale2.9250,060146,175127,940Sep 22 04:31 PM
Stewart Richard AlistairChief Executive OfficerSep 18 '25Option Exercise0.00297,5000358,376Sep 22 04:29 PM
Stewart Richard AlistairChief Executive OfficerSep 18 '25Sale2.92129,501378,143228,875Sep 22 04:29 PM
Wan JerryPrincipal Accounting OfficerSep 04 '25Option Exercise0.0034,100046,764Sep 08 04:59 PM
Wan JerryPrincipal Accounting OfficerSep 04 '25Sale2.7714,07038,97432,694Sep 08 04:59 PM
KING THOMAS BRAXTONDirectorSep 04 '25Option Exercise0.00455,0000455,000Sep 08 04:54 PM
KING THOMAS BRAXTONDirectorSep 04 '25Sale2.77139,858387,407315,142Sep 08 04:54 PM
JACOBS CINDYPresident & CMOSep 04 '25Option Exercise0.00110,0000143,214Sep 08 04:51 PM
JACOBS CINDYPresident & CMOSep 04 '25Sale2.7727,62976,532115,585Sep 08 04:51 PM
Xinos JaimeChief Commercial OfficerSep 04 '25Option Exercise0.0069,000095,286Sep 08 04:39 PM
Xinos JaimeChief Commercial OfficerSep 04 '25Sale2.7720,85457,76674,432Sep 08 04:39 PM